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(BMI) (-0.3kg.m-2) in comparison to neutral protamine Hage-
dorn insulin + human soluble insulin (NPH/HSI). The aim of this
study was to project the long-term clinical and cost outcomes
associated with IDet/IAsp versus NPH/HSI basal/bolus therapy
in the German setting based on these ﬁndings. METHODS: A
published, validated and peer-reviewed model that combines
Markov sub-models and Monte Carlo simulation was used to
simulate the progression of diabetes and its complications (car-
diovascular disease, neuropathy, renal and eye disease). Transi-
tion probabilities and HbA1c-dependent adjustments were
derived from published sources. Baseline cohort characteristics
and treatment effect data were based on the clinical study. Direct
costs were retrieved from published sources and projected over
patient lifetimes from a German National Health care perspec-
tive. Costs and clinical beneﬁts were discounted at 3.5% annu-
ally. RESULTS: IDet/IAsp treatment was associated with fewer
diabetes-related complications, improved life expectancy (0.23
life years gained) and quality-adjusted life expectancy (0.21
QALYs gained) compared to NPH/HSI. Mean total lifetime costs
were €3165 per patient higher with IDet/IAsp, leading to incre-
mental cost-effectiveness ratios (ICERs) of €13,761 per life 
year and €15,071 per QALY gained. CONCLUSIONS: Short-
term clinical beneﬁts in glycemic control, hypoglycemic event
rates and BMI associated with IDet/IAsp basal/bolus therapy
were projected to lead to fewer complications, improved life
expectancy and quality-adjusted life expectancy compared to
NPH/HSI. This resulted in ICERs for IDet/IAsp versus NPH/HSI
in the range considered to represent good value for money.
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Diabetes Mellitus type-1 (DM1) is a high-incidence, chronic
disease that increases morbidity and mortality, in Spain 5000
new diagnosed patients per year have been estimated. DM1
chronic complications are the main cause of resource health care
utilization and death among diabetic patients. DM1 is one of the
most important causes of death, occupying third place for
women and seventh for men in our country. Continuous Subcu-
taneous Insulin Infusion (CSII) reduces incidence of Diabetes-
related complications when compared with Multiple Daily
Injections (MDI) for Type-1. OBJECTIVE: The aim of the study
was to project the costs and clinical beneﬁts of CSII vs. MDI in
the long term for DM1 patients in Spain. METHODS: An adap-
tation of the CORE diabetes model was carried out for the
Spanish setting. Clinical and economic data were retrieved from
published studies and SOIKOSTM Spanish’s health care cost
database. The analysis was run over a lifetime horizon from a
NHS perspective, and direct costs and beneﬁts were actualized
to euros 2004 and discounted at 3% annum. RESULTS: Pre-
liminary results showed that treatment with CSII was associated
with an improvement in life expectancy (LE) of 0.859 and 0.836
Quality-Adjusted Life-Years (QALY’s), compared to MDI. This
was accompanied by decreases in cumulative incidence of com-
plications. Mean total lifetime costs were 25,463 € more expen-
sive with CSII treatment vs. MDI. This results in an incremental
cost effectiveness ratio of 30,453 €/QALY with CSII compared
to MDI group. CONCLUSION: Improvements in glycemic
control associated with CSII vs. MDI lead to increase LE and
QoL due to reduced incidence of diabetes-related complications.
CSII is cost effective compared to MDI according to accepted
Spanish threshold.
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OBJECTIVES: In a recent randomized, controlled clinical study
in 447 patients with type-1 diabetes, use of insulin detemir (IDet)
versus neutral protamine hagedorn (NPH) insulin in a basal
(twice daily)/bolus regimen with insulin aspart (IAsp) as bolus
insulin, demonstrated that IDet/IAsp was associated with a risk
reduction of 22% for hypoglycemic events (p = 0.029), a reduc-
tion of 0.2kg in body weight (p < 0.001) and decreased systolic
blood pressure (SBP) (3mmHg, p < 0.001) versus NPH/IAsp over
6 months of treatment. No signiﬁcant difference in HbA1c was
noted. The aim of this analysis was to assess the impact of these
changes over long-term treatment with IDet/IAsp versus
NPH/IAsp. METHODS: A peer-reviewed, validated computer
simulation model was used to project these short-term ﬁndings
to evaluate long-term clinical and cost outcomes. Transition
probabilities and risk adjustments were derived from published
studies. Baseline cohort characteristics were taken from the clin-
ical trial. Total direct costs (complications + treatment costs)
were derived from published sources and projected over patients’
lifetimes from a German National Health care perspective. Costs
and clinical beneﬁts were discounted at 3.5% annually.
RESULTS: Decreased incidence of hypoglycemic events,
improved BMI and SBP associated with IDet/IAsp treatment 
led to fewer diabetes-related complications, increased life
expectancy (0.15 years) and improved quality-adjusted life
expectancy (0.22 QALYs) compared to NPH/IAsp. Mean total
lifetime costs were €1204 per patient higher in the IDet/IAsp
treatment arm than in the NPH/IAsp group, leading to incre-
mental cost-effectiveness ratios of €8027 per LYG and €5473 per
QALY gained. CONCLUSIONS: Short-term clinical improve-
ments associated with IDet/IAsp were projected to lead to a
lower incidence of complications, improved life expectancy and
quality-adjusted life expectancy compared to NPH/IAsp. Reduc-
tions in the cost of complications partially offset the costs of
IDet/IAsp treatment, leading to incremental cost-effectiveness
ratios within the range considered to represent good value for
money.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes associated with insulin aspart + metformin (IAsp/MET)
versus human insulin + metform (HI/MET) in patients with
Type-2 diabetes in a German setting based on the ﬁndings of the
PHAZIT clinical trial. METHODS: Long-term outcomes were
